ArticlePLoS pathogens2020
High crossreactivity of human T cell responses between Lassa virus lineages.
Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- A systematic review of the immuno-inflammatory dysfunction secondary to viral hemorrhagic fevers; Ebola and Lassa fever.PLoS neglected tropical diseases · 2025Pooled it
- Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial.Nature medicine · 2026Trial
- Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.Frontiers in immunology · 2025Trial
- Evaluation of candidate reference materials for the harmonization of Lassa fever serology.Emerging microbes & infections · 2026Article
- Lassa Virus-A Persistent and Evolving Threat.Microorganisms · 2026Review
- Respiratory mucosal vaccines for emerging viruses: promise and challenges.Journal of virology · 2026Review
- Decoding the human CD4Cell reports. Medicine · 2026Article
- A Roadmap Towards the Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential.Current pharmaceutical biotechnology · 2026Article
- Robust polyfunctional CD8The Journal of general virology · 2025Article
- Infusion of neutralization into Lassa vaccine design.Trends in immunology · 2025Review
- Expansion of myeloid suppressor cells and suppression of Lassa virus-specific T cells during fatal Lassa fever.PLoS pathogens · 2025Article
- Current perspectives on vaccines and therapeutics for Lassa Fever.Virology journal · 2024Review
- Vaccine Candidates against Arenavirus Infections.Vaccines · 2023Review
- Molecular Engineering of a Mammarenavirus with Unbreachable Attenuation.Journal of virology · 2023Article
- Lassa Fever Natural History and Clinical Management.Current topics in microbiology and immunology · 2023Article
- 50 Years of Lassa Fever Research.Current topics in microbiology and immunology · 2023Article
- Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria.Scientific reports · 2022Article
- Expansion of CD8+ T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors.PLoS neglected tropical diseases · 2022Article
- Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines.Vaccines · 2022Review
- The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses-Not Just Another Brick in the Viral Nucleocapsid.Viruses · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 8 institutions in 3 countries.
Funding
Abstract
Lassa virus infects hundreds of thousands of people each year across rural West Africa, resulting in a high number of cases of Lassa fever (LF), a febrile disease associated with high morbidity and significant mortality. The lack of approved treatments or interventions underscores the need for an effective vaccine. At least four viral lineages circulate in defined regions throughout West Africa with substantial interlineage nucleotide and amino acid diversity. An effective vaccine should be designed to elicit Lassa virus specific humoral and cell mediated immunity across all lineages. Most current vaccine candidates use only lineage IV antigens encoded by Lassa viruses circulating around Sierra Leone, Liberia, and Guinea but not Nigeria where lineages I-III are found. As previous infection is known to protect against disease from subsequent exposure, we sought to determine whether LF survivors from Nigeria and Sierra Leone harbor memory T cells that respond to lineage IV antigens. Our results indicate a high degree of cross-reactivity of CD8+ T cells from Nigerian LF survivors to lineage IV antigens. In addition, we identified regions within the Lassa virus glycoprotein complex and nucleoprotein that contributed to these responses while T cell epitopes were not widely conserved across our study group. These data are important for current efforts to design effective and efficient vaccine candidates that can elicit protective immunity across all Lassa virus lineages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.